Treatment of SFA lesions with Drug-Eluting technologies

SUSTAINED RELEASE – SUPERIOR RESULTS

Eluvia demonstrated Superior Results in the World’s First Head-to-Head DES SFA Trial. Eluvia is the first and only SFA technology that sustains drug release beyond one year.
Cirse Imperial animation Post Data Release
Watch the video now
Prefer to read the study highlights? Sign-up to download the IMPERIAL Data Sheet (DES SFA).
Sign up here to download the IMPERIAL Data Sheet


The Growing Evidence Base on Drug Eluting Technologies: A new Focus on Drug Eluting Stent 

New focus on drug eluting stent
Watch the Video now
    
  • Results of the IMPERIAL Randomized Controlled Trial of Eluvia vs Zilver PTX
  • Drug Eluting Stent in Peripheral Artery Disease, Critical Limb Ischemia and Below The Knee indications 

Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies. Our commitment is to bring forward innovative therapies that can make a difference in the lives of patients, and our foundation of more than 15 years of design and development has established our clinical leadership.

Eluvia Data Sheet
Data sheet

IMPERIAL datasheet (DES SFA)

Eluvia Data Sheet
Data sheet

Ranger All-Comers Registry 12 Month-data

Did you know

DID YOU KNOW

Boston Scientific is the only company investing in a complete portfolio of Drug-Eluting Therapies.
Find out more about our clinical program

Products Overview

ELUVIATM Drug-Eluting
Vascular Stent System

The Eluvia Drug-Eluting Stent delivers unprecedented results in the SFA through its unique SUSTEND™ drug-delivery
technology.
MAJESTIC Trial

RANGERTM Paclitaxel-Coated
PTA Balloon Catheter

The Ranger Drug Coated balloon has been designed to provide consistent and predictable drug delivery through efficient drug transfer and a strong coating integrity.
RANGER SFA RCT
Learn more about Boston Scientific clinical program on Drug-Eluting Technologies
About Drug-Eluting Technologies
Clinical Program
  
Resources Center
   
News & Events
  

WANT TO KNOW MORE?

Join our Drug-Eluting Technologies Community

Sign Up for Product Updates

Receive the latest news of Drug Eluting Technologies

SIGN UP

RANGER™ - New long lenghts.

RANGER™ Product information

Disclaimer
1. Superiority determined in Post Hoc Superiority Analysis (Continuity Adjusted Chi-Square p-value). Primary patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value = 0.0210). Major adverse event rate of 4.9% in the Eluvia arm vs. 9.0% in the Zilver PTX arm (p-value = 0.0975). Primary patency defined as PSVR ≤ 2.5 without a hemodynamically significant stenosis on duplex ultrasound and without clinically-driven TLR or bypass of the target lesion.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for use only in countries with applicable health authority registrations. Material not intended for use in France. 2017 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved.

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

Professionals

Medical Specialties Reimbursement Institute for Advancing Science

Patients

Health Conditions

Products

Products

About

Who We Are Businesses EMEA Leadership Team EMEA Locations

PI-510502-AB

©2019 Boston Scientific Corporation or its affiliates. All rights reserved.